118 related articles for article (PubMed ID: 18210674)
1. Letter to the editor. Use of oral oxymorphone.
Kerwin R
Consult Pharm; 2007 Dec; 22(12):972-3; author reply 973-4. PubMed ID: 18210674
[No Abstract] [Full Text] [Related]
2. Oral oxymorphone (Opana).
Med Lett Drugs Ther; 2007 Jan; 49(1251):3-4. PubMed ID: 17179898
[No Abstract] [Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
Kaiko RF; Benziger DP; Fitzmartin RD; Burke BE; Reder RF; Goldenheim PD
Clin Pharmacol Ther; 1996 Jan; 59(1):52-61. PubMed ID: 8549034
[TBL] [Abstract][Full Text] [Related]
4. Intranasal absorption of oxymorphone.
Hussain MA; Aungst BJ
J Pharm Sci; 1997 Aug; 86(8):975-6. PubMed ID: 9269879
[TBL] [Abstract][Full Text] [Related]
5. Sedative effects and serum drug concentrations of oxymorphone and metabolites after subcutaneous administration of a liposome-encapsulated formulation in dogs.
Smith LJ; Krugner-Higby L; Trepanier LA; Flaska DE; Joers V; Heath TD
J Vet Pharmacol Ther; 2004 Oct; 27(5):369-72. PubMed ID: 15500576
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study.
Adams MP; Ahdieh H
Pharmacotherapy; 2004 Apr; 24(4):468-76. PubMed ID: 15098800
[TBL] [Abstract][Full Text] [Related]
7. The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets.
Fiske WD; Jobes J; Xiang Q; Chang SC; Benedek IH
J Pain; 2012 Jan; 13(1):90-9. PubMed ID: 22208805
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of oxymorphone in cats.
Siao KT; Pypendop BH; Stanley SD; Ilkiw JE
J Vet Pharmacol Ther; 2011 Dec; 34(6):594-8. PubMed ID: 21323677
[TBL] [Abstract][Full Text] [Related]
9. Oxymorphone: a review.
Prommer E
Support Care Cancer; 2006 Feb; 14(2):109-15. PubMed ID: 16317569
[TBL] [Abstract][Full Text] [Related]
10. Use of oral oxymorphone in the elderly.
Guay DR
Consult Pharm; 2007 May; 22(5):417-30. PubMed ID: 17658959
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and behavioral effects of oxymorphone after intravenous and subcutaneous administration to healthy dogs.
KuKanich B; Schmidt BK; Krugner-Higby LA; Toerber S; Smith LJ
J Vet Pharmacol Ther; 2008 Dec; 31(6):580-3. PubMed ID: 19000282
[No Abstract] [Full Text] [Related]
12. Oral extended-release oxymorphone: a new choice for chronic pain relief.
Matsumoto AK
Expert Opin Pharmacother; 2007 Jul; 8(10):1515-27. PubMed ID: 17661733
[TBL] [Abstract][Full Text] [Related]
13. A randomized, rater-blinded, crossover study of the effects of oxymorphone extended release, fed versus fasting, on cognitive performance as tested with CANTAB in opioid-tolerant subjects.
Spierings EL; Volkerts ER; Heitland I; Thomson H
Pain Med; 2014 Feb; 15(2):264-71. PubMed ID: 24330343
[TBL] [Abstract][Full Text] [Related]
14. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
Chan S; Edwards SR; Wyse BD; Smith MT
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of ammonium sulfate gradient loaded liposome-encapsulated oxymorphone and hydromorphone in healthy dogs.
Smith LJ; Kukanich BK; Krugner-Higby LA; Schmidt BH; Heath TD
Vet Anaesth Analg; 2013 Sep; 40(5):537-45. PubMed ID: 23601353
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats.
Pypendop BH; Ilkiw JE; Shilo-Benjamini Y
J Vet Pharmacol Ther; 2014 Jun; 37(3):295-300. PubMed ID: 24236993
[TBL] [Abstract][Full Text] [Related]
17. Comment: Oral oxymorphone for pain management.
Ahdieh H; White R
Ann Pharmacother; 2007 Dec; 41(12):2074. PubMed ID: 17971405
[No Abstract] [Full Text] [Related]
18. Effect of amantadine on oxymorphone-induced thermal antinociception in cats.
Siao KT; Pypendop BH; Escobar A; Stanley SD; Ilkiw JE
J Vet Pharmacol Ther; 2012 Apr; 35(2):169-74. PubMed ID: 21535013
[TBL] [Abstract][Full Text] [Related]
19. Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain.
Rauck R; Ma T; Kerwin R; Ahdieh H
Pain Med; 2008 Oct; 9(7):777-85. PubMed ID: 18950436
[TBL] [Abstract][Full Text] [Related]
20. A Phase I study of the pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxymorphone transdermal patch system.
Gavin PD; Simon LS; Schlagheck T; Smith AJ; Krishnarajah J
Pain Manag; 2017 Nov; 7(6):499-512. PubMed ID: 28814158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
